Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 163

Sort by

Sort Order Select

Journal Articles

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Chong Wei, Wei Zhang, Dao-Bin Zhou, Jian Li, Yan Zhang, Kaini Shen, Wei Wang, Zi Wang, Danqing Zhao, Jing Ruan, Huacong Cai, Yueying Mao

Blood (2025) 146 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2025-6322

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood (2025) 146 (Supplement 1): 927.

https://doi.org/10.1182/blood-2025-927

Published: 2025

Journal Articles

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

Guangsheng He, Yuemin Gong, Jianyong Li, Wenwei Zhu, Jingnan Sun, Chuan He, Wei Zhang, Cuicui Han, Jie Yang, Heng Liu

Blood (2025) 146 (Supplement 1): 983.

https://doi.org/10.1182/blood-2025-983

Published: 2025

Journal Articles

Construction of mindfulness based cancer rehabilitation training program for malignant hematology patients based on the Liverpool mindfulness model

Rong Fu, Jie Liu, Rongrong Wang, Jianlan Ren, Wei Zhang

Blood (2025) 146 (Supplement 1): 6423.

https://doi.org/10.1182/blood-2025-6423

Published: 2025

Journal Articles

Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study

Chong Wei, Yang Song, Shengyu Zhou, Shuangnian Xu, Hongmei Jing, Hui Liu, Wei Zhang, Dao-Bin Zhou

Blood (2025) 146 (Supplement 1): 5423.

https://doi.org/10.1182/blood-2025-5423

Published: 2025

Journal Articles

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Xiyang Liu, Liqing Kang, Hongfei Gu, Wei Zhang, Hongjia Zhu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2025-3713

Published: 2025

Journal Articles

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Xiyang Liu, Hongjia Zhu, Wei Zhang, Liqing Kang, Hongfei Gu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Peihua Lu, Lei Yu

Blood (2025) 146 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2025-2382

Published: 2025

Journal Articles

Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study

Yan Zhang, Huiying Zhu, Zhangyuting He, Danqing Zhao, Chong Wei, Jing Ruan, Jian Li, Wei Zhang, Dao-Bin Zhou

Blood (2025) 146 (Supplement 1): 5471.

https://doi.org/10.1182/blood-2025-5471

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Wei Zhang, Nan Xu, Hongfei Gu, Xiyang Liu, Liqing Kang, Hongjia Zhu, Xingyue Wang, Xue Lu, Huan Zhou, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Xiaoyan Lou, Minghao Li, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2025-4152

Published: 2025

Journal Articles

Cly-124, a first-in-class DCN1 inhibitor partially suppresses CUL3 neddylation and induces fetal hemoglobin is a new potential treatment for sickle cell disease

Blood (2025) 146 (Supplement 1): 837.

https://doi.org/10.1182/blood-2025-837

Published: 2025

Journal Articles

IFN-γ-induced CD4+ CADM1+ T cells emerged as malignancy-progressive biomarkers in EBV NK/T lymphoproliferative disorders and potential drivers of malignant expansion in AITL

Jian Li, Yan Zhang, Qinhuan Luo, Dao-Bin Zhou, Yiao Di, Wei Zhang, Chong Wei

Blood (2025) 146 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2025-3530

Published: 2025

Journal Articles

Clonal hematopoiesis in t-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution

Chong Wei, Wei Zhang, Dao-Bin Zhou

Blood (2025) 146 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2025-3521

Published: 2025

Journal Articles

Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China

Huiying Zhu, Zhangyuting He, Chong Wei, Jing Ruan, Danqing Zhao, Wei Zhang, Jian Li, Dao-Bin Zhou, Yan Zhang

Blood (2025) 146 (Supplement 1): 3693.

https://doi.org/10.1182/blood-2025-3693

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential

Ruyi Xue, Min Li, Ge Zhang, Wei Zhang, Liping Han, Tao Bo, Haoxuan Zhong, Dingjin Yao, Yiran Deng, She Chen, Si Zhang

Blood (2024) 144 (25): 2652–2665.

https://doi.org/10.1182/blood.2023023179

Published: 2024

Includes: Supplemental data

Journal Articles

Analysis of Anxiety and Depression Status and Influencing Factors in Multiple Myeloma Patients

Mengran Gao, Wei Zhang, Rong Fu

Blood (2024) 144 (Supplement 1): 7880.

https://doi.org/10.1182/blood-2024-210353

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study

Chong Wei, Shengyu Zhou, Shuangnian Xu, Hongmei Jing, Hui Liu, Wei Zhang, Daobin Zhou

Blood (2024) 144 (Supplement 1): 1691.

https://doi.org/10.1182/blood-2024-209576

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

Construction of mindfulness based cancer rehabilitation training program for malignant hematology patients based on the Liverpool mindfulness model

Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Cly-124, a first-in-class DCN1 inhibitor partially suppresses CUL3 neddylation and induces fetal hemoglobin is a new potential treatment for sickle cell disease

IFN-γ-induced CD4+ CADM1+ T cells emerged as malignancy-progressive biomarkers in EBV NK/T lymphoproliferative disorders and potential drivers of malignant expansion in AITL

Clonal hematopoiesis in t-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution

Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential

Analysis of Anxiety and Depression Status and Influencing Factors in Multiple Myeloma Patients

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only